Niche therapy Target Huntington’s disease-focused opportunities by positioning Vybion’s intrabody and intranasal exosome delivery approach as a novel therapeutic modality for polyQ disorders and other neurodegenerative conditions with unmet needs.

Orphan designation Leverage FDA Orphan Drug Designation for INT41 to pursue partnerships and grants, emphasizing potential fast-to-market incentives, reduced clinical burden, and eligibility for designation-driven market exclusivity.

IND readiness Highlight the pre-IND readiness and defined IND enabling package as a selling point for potential CROs, academic collaborations, and biotech partners seeking accelerated collaboration paths and clearer regulatory milestones.

Funding signal Capitalize on the current revenue range to identify investors and strategic acquirers focused on early-stage neurodegenerative programs, offering a lean, scalable platform with room for external funding to advance IND-enabling activities.

Tech & ops Promote the lightweight tech stack and lean operations as a proof point for cost-efficient development collaborations, CRO partnerships, and shared infrastructure agreements to support specialized preclinical and translational studies.